Thymosin Alpha-1 vs MOTS-c: Cost and Access Head-to-Head

HealthRX.com

Neither peptide has an approved US product to price

Print or save as PDF

Key numbers

  • 1.6 mgZadaxin injection strength; approved only in some other countries, not the USSource: fda.gov, as cited Nov 7, 2026
  • 0.5 mg/kg/dayMOTS-c mouse dose by injection; rodent data, not a human doseSource: fda.gov, as cited Nov 7, 2026
  • 15 mg/kgMOTS-c dose in a late-life mouse lifespan study; rodent only, not a human doseSource: fda.gov, as cited Nov 7, 2026
  • 20%Lower body weight in high-fat-diet mice treated with MOTS-c; animal result onlySource: fda.gov, as cited Nov 7, 2026
  • US marketed product / None for either peptide
  • FDA approval / Neither; MOTS-c is not part of any approved drug [1][2]
  • Approved in other countries / Thymosin alpha-1 (Zadaxin) in some, including Italy, India and Hong Kong [2]; FDA found no MOTS-c product authorized by the European Medicines Agency [1]
  • Advisory votes / MOTS-c in favour, July 2026 [5]; thymosin alpha-1, 4 yes and 17 no, December 2024 [6]
  • FDA list for state-licensed pharmacies and physicians / Neither appears in any of the three categories [7][8]
  • FDA list for outsourcing facilities / Thymosin alpha-1 in the nominated-without-adequate-support category; MOTS-c in none [7][8]
  • HHS draft peptide policy, October 2026 / Names MOTS-c; does not name thymosin alpha-1 [4]

Is there an approved US product for either peptide?

No. Thymosin alpha-1 has no US marketing application [2], and MOTS-c is not a component of any FDA-approved drug [1]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [3]. For MOTS-c, FDA found it marketed on websites and in combinations, and no outsourcing facility reported compounding it from January 2017 to December 2025 [1].

The one finished product is sold abroad. Zadaxin is a 1.6 mg thymalfasin injection approved in some other countries, including Italy, India and Hong Kong, and it is not interchangeable with bulk thymosin alpha-1 powder [2].

Where access actually differs

Thymosin alpha-1 appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians. It sits in category 3 (nominated without adequate support) on the outsourcing facility list. FDA's interim policy of not acting against compounders of certain nominated substances therefore does not reach it [7][8][9]. FDA still posts immunogenicity and characterization concerns for it on its safety-risk page, where it sits in the nominated-but-withdrawn table [10].

MOTS-c is in none of the three categories on either list [7][8][9]. FDA staff proposed in July 2026 that neither its free base nor its acetate be added, citing no human safety or effectiveness data and no animal toxicity studies [1]. The committee voted in favour on July 23, 2026, against staff's recommendation. That is advice only; MOTS-c is not on the list, and adding it takes rulemaking [5][11].

Questions worth asking

Choose the questions you want to keep

The October 2026 HHS draft names MOTS-c only

The draft enforcement-discretion policy was filed October 28, 2026 (Federal Register document 2026-22192; publication scheduled October 30, 2026; comments due two weeks after). It names six peptides (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) and covers MOTS-c acetate by subcutaneous or intramuscular injection [11][4]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding it where conditions are met. Examples are a single active ingredient, a patient-specific prescription and an FDA-registered manufacturer with a certificate of analysis [4]. The notice says it creates no rights and is not binding on HHS or the public [11]. Thymosin alpha-1 is not among the six [4].

What human data sits behind each

A 2026 Cochrane review of 10 randomized trials and 1349 adults with chronic hepatitis B found possible lower all-cause mortality with thymosin alpha-1 (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people), but at very low certainty. The reviewers said they are not sure it helps [12].

FDA found no published study in which MOTS-c was given to a human [1]. All MOTS-c pharmacology comes from cells and rodents. In mice on a high-fat diet, MOTS-c treatment produced about 20% lower body weight after 8 weeks at 0.5 mg/kg/day by intraperitoneal injection [1][13]. A late-life schedule of 15 mg/kg three times weekly beginning at 23.5 months increased median lifespan from 912 to 970 days in mice [1][14]. FDA says no dose-response relationships were assessed, and there is no approved or human-tested dose of MOTS-c. The rodent doses cannot be converted into human doses [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. How did thymosin alpha-1 fare in the December 2024 advisory vote?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is either peptide FDA-approved?
No. Thymosin alpha-1 has no US marketing application, and its four orphan drug designations are not approvals [2]. MOTS-c is not an FDA-approved drug and is not a component of one [1].
Does the HHS draft make MOTS-c legal to compound?
It is a draft statement that HHS does not intend to take enforcement action against certain pharmacies and physicians where its conditions are met (acetate form, injection only). It creates no rights, is not binding on HHS or the public, and is not an approval or a listing [11][4].
Is there an approved product I could look up a cost for?
Not in the US. Neither peptide has an FDA-approved product, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3]. Zadaxin, the thymalfasin injection, is approved only in some other countries [2].
Are these peptides banned in sport?
MOTS-c is named in WADA section S4.4.1 and prohibited at all times, in and out of competition [15]. Thymosin alpha-1 is not named on the Prohibited List [15].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

How much does MOTS-c peptide cost?

No MOTS-c price is established. Neither peptide has an FDA-approved US product, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing. MOTS-c also has no approved or human-tested dose, so no dose-based cost can be set.

How much does thymosin alpha 1 cost?

No thymosin alpha-1 price is established. It has no US marketing application, so there is no FDA-approved product to price. The one finished product, Zadaxin, is approved only in some other countries, including Italy, India and Hong Kong, and is not interchangeable with bulk thymosin alpha-1 powder.

Show all 15 referencesHide references
  1. U.S. Food and Drug Administration.
  2. U.S. Food and Drug Administration.
  3. Human Drug Compounding Laws | FDA.
  4. Official web page.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. U.S. Food and Drug Administration.
  8. U.S. Food and Drug Administration.
  9. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA.
  10. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  11. Official web page.
  12. Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.
  13. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  14. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
  15. World Anti-Doping Agency.
Evidence overview for Thymosin Alpha-1 vs MOTS-c: Cost and Access Head-to-Head